Want to see ROIV full AI Analyst Report?
Top Page
Roivant Sciences
(NASDAQ:ROIV)
Select Model
Select Model
Rating:65Neutral
Price Target:
$40.00
▲(9.68% Upside)
Action:Reiterated
Date:08/28/26
The score is driven by strong balance-sheet flexibility but meaningfully offset by persistent unprofitability and substantial cash burn. Technicals are supportive with price above key moving averages and positive momentum indicators. The latest earnings call and the FDA approval event add optimism via near-term commercialization and a busy catalyst calendar, while valuation remains constrained by ongoing losses and no indicated dividend yield.
Positive Factors
FDA approval strengthens commercial platform
LISRAYA approval creates an immediate commercial product in an underserved autoimmune indication. Its first-in-class positioning, oral dosing and specialty support infrastructure may improve adoption and establish a platform for future launches.
Negative Factors
Substantial ongoing cash burn
Persistent operating and free-cash-flow deficits show that development and operating costs are consuming significant cash. Even with strong liquidity, continued burn could reduce flexibility before the portfolio reaches broader commercial scale.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA approval strengthens commercial platform
LISRAYA approval creates an immediate commercial product in an underserved autoimmune indication. Its first-in-class positioning, oral dosing and specialty support infrastructure may improve adoption and establish a platform for future launches.
Read all positive factors
Roivant Sciences (ROIV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.34B
Dividend YieldN/A
Average Volume (3M)5.59M
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-67.58%
EPS Growth45.61%
CountryUS
Employees721
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding722,323,000
10 Day Avg. Volume4,163,867
30 Day Avg. Volume5,587,777
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.25Price Target Upside15.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$51.17M
Roivant Sciences Business Overview & Revenue Model
Company Description
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of so...
How the Company Makes Money
Roivant makes money primarily through (1) product and service-related economics tied to medicines it commercializes through its subsidiaries and (2) partnering and portfolio monetization activities. Where Roivant (directly or via a subsidiary) has...
Roivant Sciences Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.Positive Updates
Potential Near-Term Launch of Brepocitinib in Dermatomyositis (DM)
Priority review and a PDUFA this quarter with a potential launch by end of September; commercial and patient-support teams built and ready; company guiding a "slow and steady" launch strategy to lay groundwork across multiple indications.
Negative Updates
Quiet Quarter with Limited New Commercial Metrics
Management described the quarter as "quiet" with limited near-term revenue signals; they will provide more launch metrics only after potential approval and expect early launch visibility to be limited while pursuing a "slow and steady" approach.
Read all updates
Q1-2026 Updates
Positive
Negative
Potential Near-Term Launch of Brepocitinib in Dermatomyositis (DM)
Priority review and a PDUFA this quarter with a potential launch by end of September; commercial and patient-support teams built and ready; company guiding a "slow and steady" launch strategy to lay groundwork across multiple indications.
Read all positive updates
Company Guidance
Management's guidance was a "slow and steady" commercial approach with limited early launch metrics to be disclosed: brepocitinib has priority review/PDUFA this quarter and is expected to launch by end‑September, while a busy 2H26 is planned with topline readouts for NIU, mosli (PH‑ILD) and CLE, D2T‑RA updates including the Part‑2 randomized‑withdrawal data and an FDA discussion, and ongoing LPP enrollment; mosli is expected to show a clear PVR signal (study not powered for 6‑minute walk). The cutaneous sarcoidosis Phase III is now enrolling (16‑week, 140 patients across ~70 sites, 3:2 randomization, 45 mg with a mandatory steroid taper weeks 2–8) with topline in 2028. Financially, Q1 R&D expense was about $200M, non‑GAAP adjusted G&A just under $100M (GAAP G&A $166M), cash was just under $4B (pre‑receipt of proceeds from the Moderna settlement), Roivant reported the ~$950M Moderna settlement (≈$770M to Genevant, remainder to Arbutus), expects to receive roughly $772M, executed ~ $200M of share repurchases in the quarter (prior buybacks totaled ~$1.5B at ~ $10/share; recent repurchases averaged in the high‑$20s), and noted potential additional legal upside (~$1.3B from the 1498 appellate) plus three international suits filed; by end‑2028 the company is targeting 3+ commercial launches, 9+ pivotal readouts and 4+ NDA/BLA filings.Roivant Sciences Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
78
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.53M | 8.26M | 29.05M | 32.71M | 31.53M | 55.29M |
| Gross Profit | 6.12M | 6.97M | 28.14M | 31.11M | 28.50M | 46.32M |
| EBITDA | -281.34M | -261.23M | -667.52M | 4.62B | -838.16M | -910.77M |
| Net Income | -266.25M | -299.77M | -171.98M | 4.35B | -1.01B | -845.26M |
Balance Sheet | ||||||
| Total Assets | 5.31B | 5.73B | 5.44B | 7.22B | 2.39B | 2.59B |
| Cash, Cash Equivalents and Short-Term Investments | 3.84B | 4.30B | 4.89B | 6.54B | 1.68B | 2.06B |
| Total Debt | 107.15M | 107.44M | 100.17M | 499.75M | 481.40M | 283.89M |
| Total Liabilities | 384.62M | 435.63M | 249.74M | 773.95M | 782.02M | 523.70M |
| Stockholders Equity | 4.23B | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | -813.95M | -758.56M | -844.05M | -766.65M | -856.08M | -695.16M |
| Operating Cash Flow | -809.36M | -750.35M | -839.45M | -765.27M | -843.39M | -677.73M |
| Investing Cash Flow | 684.64M | -682.33M | -1.77B | 5.20B | -44.27M | 303.30M |
| Financing Cash Flow | -66.23M | 134.24M | -1.22B | 419.36M | 499.46M | 306.79M |
Roivant Sciences Technical Analysis
Positive
36.47
Price Trends
34.87
Positive
31.91
Positive
27.99
Positive
Market Momentum
0.66
Positive
59.09
Neutral
41.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ROIV, the sentiment is Positive. The current price of 36.47 is above the 20-day moving average (MA) of 35.79, above the 50-day MA of 34.87, and above the 200-day MA of 27.99, indicating a bullish trend. The MACD of 0.66 indicates Positive momentum. The RSI at 59.09 is Neutral, neither overbought nor oversold. The STOCH value of 41.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ROIV.
Roivant Sciences Risk Analysis
Roivant Sciences disclosed 97 risk factors in its most recent earnings report. Roivant Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Roivant Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $11.34B | 61.86 | 8.90% | 0.45% | -0.38% | 152.71% | |
79 Outperform | $16.89B | 16.40 | 21.37% | ― | 12.59% | ― | |
78 Outperform | $13.36B | 230.38 | 8.37% | ― | 16.02% | -59.24% | |
78 Outperform | $12.41B | 30.41 | 180.63% | ― | 41.15% | -21.44% | |
65 Neutral | $26.34B | -96.71 | -6.12% | ― | -67.58% | 45.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ROIV
Roivant Sciences
36.75
24.81
207.79%
CORT
Corcept Therapeutics
119.80
50.22
72.16%
HALO
Halozyme
107.06
34.25
47.04%
JAZZ
Jazz Pharmaceuticals
249.29
123.16
97.65%
TECH
Bio-Techne
72.38
18.36
33.98%
Roivant Sciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Roivant Gains FDA Approval for LISRAYA Dermatomyositis Therapy
Positive
Aug 27, 2026
On August 27, 2026, Roivant announced that the U.S. Food and Drug Administration approved LISRAYA (brepocitinib) 30 mg, a once-daily oral pill, for the treatment of adults with dermatomyositis, a rare systemic autoimmune disease marked by progress...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.